246 related articles for article (PubMed ID: 27780792)
1. Application of anti-Sclerostin therapy in non-osteoporosis disease models.
Jacobsen CM
Bone; 2017 Mar; 96():18-23. PubMed ID: 27780792
[TBL] [Abstract][Full Text] [Related]
2. Reversing LRP5-dependent osteoporosis and SOST deficiency-induced sclerosing bone disorders by altering WNT signaling activity.
Chang MK; Kramer I; Keller H; Gooi JH; Collett C; Jenkins D; Ettenberg SA; Cong F; Halleux C; Kneissel M
J Bone Miner Res; 2014 Jan; 29(1):29-42. PubMed ID: 23901037
[TBL] [Abstract][Full Text] [Related]
3. Sclerostin inhibition reverses skeletal fragility in an Lrp5-deficient mouse model of OPPG syndrome.
Kedlaya R; Veera S; Horan DJ; Moss RE; Ayturk UM; Jacobsen CM; Bowen ME; Paszty C; Warman ML; Robling AG
Sci Transl Med; 2013 Nov; 5(211):211ra158. PubMed ID: 24225945
[TBL] [Abstract][Full Text] [Related]
4. Effects of sclerostin antibodies in animal models of osteoporosis.
Ominsky MS; Boyce RW; Li X; Ke HZ
Bone; 2017 Mar; 96():63-75. PubMed ID: 27789417
[TBL] [Abstract][Full Text] [Related]
5. Role of Wnt signaling and sclerostin in bone and as therapeutic targets in skeletal disorders.
Marini F; Giusti F; Palmini G; Brandi ML
Osteoporos Int; 2023 Feb; 34(2):213-238. PubMed ID: 35982318
[TBL] [Abstract][Full Text] [Related]
6. Targeting the LRP5 pathway improves bone properties in a mouse model of osteogenesis imperfecta.
Jacobsen CM; Barber LA; Ayturk UM; Roberts HJ; Deal LE; Schwartz MA; Weis M; Eyre D; Zurakowski D; Robling AG; Warman ML
J Bone Miner Res; 2014 Oct; 29(10):2297-306. PubMed ID: 24677211
[TBL] [Abstract][Full Text] [Related]
7. Sclerostin Antibody Reverses Bone Loss by Increasing Bone Formation and Decreasing Bone Resorption in a Rat Model of Male Osteoporosis.
Li X; Ominsky MS; Villasenor KS; Niu QT; Asuncion FJ; Xia X; Grisanti M; Wronski TJ; Simonet WS; Ke HZ
Endocrinology; 2018 Jan; 159(1):260-271. PubMed ID: 29069393
[TBL] [Abstract][Full Text] [Related]
8. [Monoclonal antibodies to sclerostin for the treatment of osteoporosis].
Soen S
Clin Calcium; 2013 Jun; 23(6):884-9. PubMed ID: 23719502
[TBL] [Abstract][Full Text] [Related]
9. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis.
Li X; Ominsky MS; Warmington KS; Morony S; Gong J; Cao J; Gao Y; Shalhoub V; Tipton B; Haldankar R; Chen Q; Winters A; Boone T; Geng Z; Niu QT; Ke HZ; Kostenuik PJ; Simonet WS; Lacey DL; Paszty C
J Bone Miner Res; 2009 Apr; 24(4):578-88. PubMed ID: 19049336
[TBL] [Abstract][Full Text] [Related]
10. Co-deletion of Lrp5 and Lrp6 in the skeleton severely diminishes bone gain from sclerostin antibody administration.
Lim KE; Bullock WA; Horan DJ; Williams BO; Warman ML; Robling AG
Bone; 2021 Feb; 143():115708. PubMed ID: 33164872
[TBL] [Abstract][Full Text] [Related]
11. The binding between sclerostin and LRP5 is altered by DKK1 and by high-bone mass LRP5 mutations.
Balemans W; Piters E; Cleiren E; Ai M; Van Wesenbeeck L; Warman ML; Van Hul W
Calcif Tissue Int; 2008 Jun; 82(6):445-53. PubMed ID: 18521528
[TBL] [Abstract][Full Text] [Related]
12. The sclerostin story: from human genetics to the development of novel anabolic treatment for osteoporosis.
Yavropoulou MP; Xygonakis C; Lolou M; Karadimou F; Yovos JG
Hormones (Athens); 2014; 13(4):323-37. PubMed ID: 25555179
[TBL] [Abstract][Full Text] [Related]
13. Clinical utility of anti-sclerostin antibodies.
McClung MR
Bone; 2017 Mar; 96():3-7. PubMed ID: 28115281
[TBL] [Abstract][Full Text] [Related]
14. Sclerostin antibody treatment enhances metaphyseal bone healing in rats.
Agholme F; Li X; Isaksson H; Ke HZ; Aspenberg P
J Bone Miner Res; 2010 Nov; 25(11):2412-8. PubMed ID: 20499342
[TBL] [Abstract][Full Text] [Related]
15. Effect of sclerostin antibody treatment in a mouse model of severe osteogenesis imperfecta.
Roschger A; Roschger P; Keplingter P; Klaushofer K; Abdullah S; Kneissel M; Rauch F
Bone; 2014 Sep; 66():182-8. PubMed ID: 24953712
[TBL] [Abstract][Full Text] [Related]
16. Sclerostin antibody prevented progressive bone loss in combined ovariectomized and concurrent functional disuse.
Zhang D; Hu M; Chu T; Lin L; Wang J; Li X; Ke HZ; Qin YX
Bone; 2016 Jun; 87():161-8. PubMed ID: 26868528
[TBL] [Abstract][Full Text] [Related]
17. Enhanced Wnt signaling improves bone mass and strength, but not brittleness, in the Col1a1(+/mov13) mouse model of type I Osteogenesis Imperfecta.
Jacobsen CM; Schwartz MA; Roberts HJ; Lim KE; Spevak L; Boskey AL; Zurakowski D; Robling AG; Warman ML
Bone; 2016 Sep; 90():127-32. PubMed ID: 27297606
[TBL] [Abstract][Full Text] [Related]
18. Sclerostin and Bone Aging: A Mini-Review.
Hay E; Bouaziz W; Funck-Brentano T; Cohen-Solal M
Gerontology; 2016; 62(6):618-623. PubMed ID: 27177738
[TBL] [Abstract][Full Text] [Related]
19. Targeting sclerostin as potential treatment of osteoporosis.
Papapoulos SE
Ann Rheum Dis; 2011 Mar; 70 Suppl 1():i119-22. PubMed ID: 21339215
[TBL] [Abstract][Full Text] [Related]
20. Sclerostin inhibition promotes TNF-dependent inflammatory joint destruction.
Wehmeyer C; Frank S; Beckmann D; Böttcher M; Cromme C; König U; Fennen M; Held A; Paruzel P; Hartmann C; Stratis A; Korb-Pap A; Kamradt T; Kramer I; van den Berg W; Kneissel M; Pap T; Dankbar B
Sci Transl Med; 2016 Mar; 8(330):330ra35. PubMed ID: 27089204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
